C. 96

To: Board of Supervisors

From: Anna Roth, Health Services Director

Date: January 5, 2021

Subject: Purchase Order with ASD Specialty Healthcare, LLC

RECOMMENDATION(S):

APPROVE and AUTHORIZE the Purchasing Agent, on behalf of the Health Services Department, to execute a purchase order with ASD Specialty Healthcare, LLC., in an amount not to exceed \$295,000 for the purchase of Remdesivir medication for treatment of COVID-19 patients, for the period from January 1, 2021 through December 31, 2021.

FISCAL IMPACT:

This purchase order will result in an annual expenditure of up to \$295,000 and will be 100% funded by Hospital Enterprise Fund I revenues.

BACKGROUND:

Contra Costa Regional Medical Center (CCRMC) Pharmacy Department has been purchasing Remdesivir for the treatment of COVID-19 patients at CCRMC from ASD Healthcare. ASD Healthcare is the only Federal Government authorized distributer. Remdesevir prevents the virus from producing a particular enzyme that is necessary for the virus to replicate itself. Once this happens, the virus is no longer able to spread within the body. Research shows that when patients with moderate COVID-19 receive remdesivir, their symptoms improve more quickly. The drug has also been shown to shorten the

APPROVE	OTHER
RECOMMENDATION OF CN ADMINISTRATOR	TY RECOMMENDATION OF BOARD COMMITTEE
Action of Board On: 01/05/2021 APPROVED AS RECOMMENDED OTHER	
Clerks Notes:	
VOTE OF SUPERVISORS	
 AYE: John Gioia, District I Supervisor Candace Andersen, District II Supervisor Diane Burgis, District III Supervisor Karen Mitchoff, District IV Supervisor Federal D. Glover, District V Supervisor Contact: Jaspreet Benepal, 925-370-5101 	I hereby certify that this is a true and correct copy of an action taken and entered on the minutes of the Board of Supervisors on the date shown. ATTESTED: January 5, 2021 Monica Nino, County Administrator and Clerk of the Board of Supervisors By: June McHuen, Deputy



Contra Costa County duration of patient hospital stays. Among severely ill COVID-19 patients, remdesivir

BACKGROUND: (CONT'D)

has been associated with fewer deaths.

Only hospitalized COVID-19 patients may be treated with remdesivir, whether they have mild, moderate or severe disease.

ASD by the FDA ruling is the sole source for providing remdesevir. Wholesalers do not carry this medication by the FDA's decision at this time.

CONSEQUENCE OF NEGATIVE ACTION:

If this contract is not approved, CCRMC use Remdesivir to treat COVID-19 patients causing a negative impact in the health of patients.